KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2026)

Aquestive Therapeutics has reported Free Cash Flow over the past 9 years, most recently at -$8.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 25.24% year-over-year to -$8.0 million; the TTM value through Dec 2025 reached -$52.5 million, down 46.45%, while the annual FY2025 figure was -$52.5 million, 46.45% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$8.0 million at Aquestive Therapeutics, up from -$12.9 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $8.8 million in Q1 2023 and troughed at -$23.5 million in Q1 2025.
  • A 5-year average of -$7.0 million and a median of -$8.0 million in 2025 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: soared 197.63% in 2022 and later crashed 378.78% in 2024.
  • Year by year, Free Cash Flow stood at -$8.6 million in 2021, then soared by 197.63% to $8.4 million in 2022, then plummeted by 159.09% to -$5.0 million in 2023, then decreased by 29.55% to -$6.4 million in 2024, then fell by 25.24% to -$8.0 million in 2025.
  • Business Quant data shows Free Cash Flow for AQST at -$8.0 million in Q4 2025, -$12.9 million in Q3 2025, and -$8.0 million in Q2 2025.